浏览全部资源
扫码关注微信
1.辽宁省药品检验检测院/国家药品监督管理局化学药品质量研究与评价重点实验室,沈阳 110036
2.辽宁省检验检测认证中心,沈阳 110036
Published:15 August 2023,
Received:10 January 2023,
Revised:10 July 2023,
扫 描 看 全 文
李尚颖,岳青阳,张耀文等.GC-MS/MS法同时测定氯沙坦钾原料药及其制剂中6种N-亚硝胺类基因毒性杂质 Δ[J].中国药房,2023,34(15):1830-1834.
LI Shangying,YUE Qingyang,ZHANG Yaowen,et al.Simultaneous determination of 6 kinds of N-nitrosamines genotoxic impurities in losartan potassium raw material and its formulations by GC-MS/MS[J].ZHONGGUO YAOFANG,2023,34(15):1830-1834.
李尚颖,岳青阳,张耀文等.GC-MS/MS法同时测定氯沙坦钾原料药及其制剂中6种N-亚硝胺类基因毒性杂质 Δ[J].中国药房,2023,34(15):1830-1834. DOI: 10.6039/j.issn.1001-0408.2023.15.08.
LI Shangying,YUE Qingyang,ZHANG Yaowen,et al.Simultaneous determination of 6 kinds of N-nitrosamines genotoxic impurities in losartan potassium raw material and its formulations by GC-MS/MS[J].ZHONGGUO YAOFANG,2023,34(15):1830-1834. DOI: 10.6039/j.issn.1001-0408.2023.15.08.
目的
2
建立同时测定氯沙坦钾原料药及其制剂中6种
N
-亚硝胺类基因毒性杂质含量的方法。
方法
2
采用气相色谱-串联质谱(GC-MS/MS)法测定氯沙坦钾原料药、氯沙坦钾片、氯沙坦钾胶囊、氯沙坦钾氢氯噻嗪片中
N
-亚硝基二甲胺(NDMA)、
N
-亚硝基二乙胺(NDEA)、
N
-亚硝基-
N
-乙基异丙胺(NEiPA)、
N
-亚硝基二异丙胺(NDiPA)、
N
-亚硝基二苯胺(NDPA)、
N
-亚硝基二丁胺(NDBA)6种
N
-亚硝胺类基因毒性杂质含量。色谱柱为SHIMADZU SH-L-17Sil MS毛细管柱;采用程序升温;进样口温度为250 ℃;进样量为1 μL;载气为氦气,流速为1 mL/min。离子源为电子轰击源,离子源温度为250 ℃;溶剂延迟时间为3.1 min;采集模式为多反应监测模式。
结果
2
NDMA、NDEA、NEiPA、NDiPA、NDPA、NDBA与其相邻色谱峰之间的分离效果均良好,分离度均大于3.8;其线性范围分别为4.9~486.0、4.9~488.5、4.5~451.5、6.8~683.5、5.2~525.0、5.2~520.0 ng/mL(
r
≥0.999 8),定量限分别为4.86、4.88、4.52、6.84、5.25、5.20 ng/mL,检测限分别为0.97、0.98、0.90、1.37、1.05、1.04 ng/mL,重复性试验的RSD为2.2%~5.6%(
n
=6),精密度试验的RSD为0.5%~1.4%(
n
=6),稳定性试验的RSD为1.5%~3.4%(
n
=5),低、中、高质量浓度回收率溶液的平均加样回收率为83.4%~103.0%(RSD为1.2%~6.3%,
n
=3)。在氯沙坦钾原料药及其制剂中均未检出6种
N
-亚硝胺类基因毒性杂质。
结论
2
该法分离效果好、准确性高、灵敏、简便,可用于氯沙坦钾原料药及其制剂中6种
N
-亚硝胺类基因毒性杂质的检测。
OBJECTIVE
2
To establish a method for simultaneous determination of the contents of 6 kinds of
N
-nitrosamines genotoxic impurities in losartan potassium raw material and its formulations.
METHODS
2
GC-MS/MS was adopted to determine 6 kinds of
N
-nitrosamines genotoxic impurities in losartan potassium raw material, Losartan potassium tablet, Losartan potassium capsule and Losartan potassium hydrochlorothiazide tablets, such as
N
-nitrosodimethylamine (NDMA),
N
-nitrosodiethylamine (NDEA),
N
-ethyl-
N
-nitroso-2-propanamine (NEiPA),
N
-nitrosodiisopropylamine (NDiPA),
N
-nitrosodipropylamine (NDPA) and
N
-nitrosodibutylamine (NDBA). The separation was performed on SHIMADZU SH-L-17Sil MS capillary column by temperature-programmed GC, with injector temperature of 250 ℃, sample size of 1 μL, carrier gas of helium, and carrier flow rate of 1 mL/min. Electron ionization and multiple reaction monitoring (MRM) data acquisition mode were used, with an ion source temperature of 250 ℃ and solvent delay time of 3.1 min.
RESULTS
2
The separation among NDMA, NDEA, NEiPA, NDiPA, NDPA, NDBA and adjacent chromatographic peaks was good, and the separation rate was higher than 3.8; the linear ranges of them were 4.9-486.0, 4.9-488.5, 4.5-451.5, 6.8-683.5, 5.2-525.0 and 5.2-520.0 ng/mL(all
r
≥0.999 8). The limits of quantitation were 4.86, 4.88, 4.52, 6.84, 5.25 and 5.20 ng/mL; the limits of detection were 0.97, 0.98, 0.90, 1.37, 1.05 and 1.04 ng/mL. RSDs of repeatability tests were 2.2%-5.6%(
n
=6), those of precision tests were 0.5%-1.4%(
n
=6), and those of stability tests were 1.5%-3.4%(
n
=5), respectively. Average recoveries of low-, medium- and high-concentration solution were 83.4%- 103.0% (RSDs were 1.2%-6.3%,
n
=3), respectively. No one among the 6 kinds of
N-
nitrosamines genotoxic impurities was detected in both losartan potassium raw material and formulations.
CONCLUSIONS
2
The method is good in separation effect, highly accurate, sensitive and simple. It can be used in the determination of the 6 kinds of
N-
nitrosamines genotoxic impurities.
气相色谱-串联质谱法氯沙坦钾原料药制剂N-亚硝胺类基因毒性杂质
losartan potassiumraw materialformulationsN-nitrosaminesgenotoxic impurities
史立川,蒲旭峰,余永秀,等. 氯沙坦钾片仿制药与原研药溶出曲线的相似性评价[J]. 中国药房,2017,28(30):4298-4301.
WEBER M A. Clinical experience with the angiotensin Ⅱ receptor antagonist losartan:a preliminary report[J]. Am J Hypertens,1992,5(12 Pt 2):247S-251S.
闫佳琳,张芸楠,韩嘉伦,等. 氯沙坦对比其他血管紧张素受体拮抗剂对血尿酸水平影响的Meta分析[J]. 临床药物治疗杂志,2022,20(3):46-52.
耿荣凯. 氯沙坦钾片治疗原发性高血压的临床分析[J]. 现代养生,2016,16(22):147.
廖腾火生. 氯沙坦钾生产过程中亚硝胺类基因毒性杂质控制技术的产业化研究[J]. 中国化工贸易,2020(9):100,103.
李彩霞,朱坤丹,何佳佳,等. GC-MS法测定氯沙坦钾中痕量的N-亚硝基二甲胺和N-亚硝基二乙胺[J]. 华西药学杂志,2022,37(4):425-428.
MILLS A L,ALEXANDER M. N-nitrosamine formation by cultures of several microorganisms[J]. Appl Environ Microbiol,1976,31(6):892-895.
杨竹,杭太俊,郭晓迪,等. N-亚硝胺类基因毒性杂质的研究进展[J]. 药学与临床研究,2020,28(4):270-274.
国家药典委员会. 关于缬沙坦国家标准修订稿的公示:第二次[EB/OL]. [2023-04-04]. https://www.chp.org.cn/ydw/upload/userfiles/20190102/14561546393538788.pdfhttps://www.chp.org.cn/ydw/upload/userfiles/20190102/14561546393538788.pdf.
FDA. GC/MS headspace method for detection of NDMA in valsartan drug substance and drug products[EB/OL]. [2023-04-04]. https://www.fda.gov/media/115965/downloadhttps://www.fda.gov/media/115965/download.
FDA. Combine direct injection N-Nitrosodimethylamine (NDMA) and N-Nitrosodimethylamine (NDEA) impurity assay by GC/MS[EB/OL]. [2023-04-04]. https://www.fda.gov/media/117807/downloadhttps://www.fda.gov/media/117807/download.
葛雨琦,叶晓霞,乐健,等. 厄贝沙坦制剂中N-亚硝胺类基因毒性杂质的GC-MS/MS测定[J]. 中国医药工业杂志,2020,51(6):759-764.
周刚,李鹏飞,高家敏. GC-MS/MS法测定阿莫西林原料药中12种N-亚硝胺类基因毒性杂质[J].中国抗生素杂志,2021,46(4):291-296.
刘博,张佟,黄露,等. 液相-高分辨质谱技术测定盐酸二甲双胍缓释片中7种亚硝胺杂质的方法学研究[J]. 中国药物警戒,2021,18(5):454-458,468.
徐艳梅,韩彬,郝丽娟,等.高效液相色谱-串联质谱法同时测定3种N-亚硝胺类基因毒性杂质[J]. 医药导报,2022,41(11):1672-1676.
赵丽,师真,洪雪花,等.气相色谱-质谱法/MRM测定生活饮用水中N-二甲基亚硝胺(NDMA)的方法研究[J].湖北农业科学,2018,57(7):108-110,113.
李俊,陈红波,王英瑛,等. GC-MS测定坎地沙坦酯中微量的N-亚硝基二甲胺和N-亚硝基二乙胺[J].中国现代应用药学,2020,37(13):1615-1620.
0
Views
1
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution